Drug Trial Radar · NCT07640217
A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Mar 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).
Conditions
- Adult Participants With Elevated Lipoprotein(a)
Interventions
SYH2068 Dose 1Drug
Administered by subcutaneous injection.
SYH2068 Dose 2Drug
Administered by subcutaneous injection.
SYH2068 Dose 3Drug
Administered by subcutaneous injection.
PlaceboDrug
Administered by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in Lp(a) from baseline to Day 60~180Time frame: Day 60~180
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.